You are here

SINGAPORE'S FUTURE ECONOMY

Biotech firm shows the way onto the global stage

InvitroCue debuts on the ASX just four years after its birth; sales growth has doubled and is 'sustainable', says founder

BT_20160128_CHINVITROCUE28_2089399.jpg
Some members of the InvitroCue team - (from left) scientific development director of the cell-based unit Abhishek Ananthanarayanan, co-founder Dr Steven Fang and technical director of the pathology unit Xu Shuoyu. Co-founder Hanry Yu was absent.

Singapore

SUCCESS stories in the Singapore life sciences sphere are few and far between, but InvitroCue, which targets profitability in seven years, could light the way for other homegrown biotechnology firms seeking to get on the global stage.

The biotech firm, a spin-off from the

sentifi.com

Market voices on:

grab

Receive $80 Grab vouchers valid for use on all Grab services except GrabHitch and GrabShuttle when you subscribe to BT All-Digital at only $0.99*/month.

Find out more at btsub.sg/promo

Powered by GET.comGetCom